Using Zebrafish to Combat Cognitive Decline: How a Biopharmaceutical Company Leveraged a Zebrafish Model to characterize a Compound for Neurodegenerative Disease Therapeutics
New drugs, No Animals, No Problem. The FDA announced legislative changes – drugs are no longer required to be tested in animals before moving to human trials. What does that mean?
Model organisms are essential to experimental research, allowing researchers and scientists to address a variety of questions. While no model is perfect, some models are
In an effort to create better models for epilepsy, we’ve been working on a grant-funded project to humanize important synaptic machinery by replacing endogenous coding
June is Alzheimer’s & Brain Awareness Month. We wanted to take a few moments to spotlight some of the awe-inspiring research on Alzheimer’s disease taking
We use the zebrafish (Danio rerio) as an in vivo model to measure the functional effects of patient-derived genetic variation. In this way, human genetic variants identified
While advances in molecular imaging, high-throughput screening, genomics and techniques like CRISPR-Cas9 gene editing have dramatically enhanced our understanding of the human body and disease,
C. elegans as a model to evaluate the function of disease genes In 1998, the soil nematode Caenorhabditis elegans became the first multicellular organism of
Neurotoxin exposure is implicated in the etiology of neurodegenerative diseases including Parkinson’s disease, Alzheimer’s disease and ALS (amyotrophic lateral sclerosis). Traditionally, vertebrate animals such as
NemaMetrix is the market leader for early preclinical in-vivo testing using small animal models to gain a better understanding of the efficacy, mode of action,
NemaMetrix is the market leader for early preclinical in-vivo testing using small animal models to gain a better understanding of the efficacy, mode of action,
How are extreme weather events, such as Hurricane Katrina, spreading heartworms and other parasitic nematodes and what are the implications of their spread?
How are extreme weather events, such as Hurricane Katrina, spreading heartworms and other parasitic nematodes and what are the implications of their spread?
Drug resistance in many pathogens — viruses, bacteria, protozoa, parasitic worms and more — presents a growing and potentially catastrophic challenge to human and animal
NemaMetrix is the market leader for early preclinical in-vivo testing using small animal models to gain a better understanding of the efficacy, mode of action,
The shift towards preventive medicine has given anti-aging startups a favorable environment in pursuing longevity and aging issues. The nematode C. elegans has emerged to
NemaMetrix is the market leader for early preclinical in-vivo testing using small animal models to gain a better understanding of the efficacy, mode of action,
Animal testing in the research-based pharmaceutical industry has been reduced in recent years both for ethical and cost reasons. However, it is still a staple
When you receive your genomic report, you have a movement of trepidation.What will it say? Will it have something that says you should do countermeasures
In 2017, a now-redacted paper published in Nature Methods claimed that CRISPR created hundreds of unintended mutations in mouse models, and that algorithms designed to
Humanized model organisms are powerful biological models that allow scientists to study human disease genes in simpler contexts without losing the value of in vivo
There is a significant pressure to increase diagnostic yield and it has its consequences. BRCA testing is probably the most developed ecosystem for genetic tests
C. elegans is one of the most powerful model organisms and has been used to unravel several key genetic pathways. The C. elegans nematode has been used
The Child Neurology Society honored William (Bill) Dobyns for his highly impactful efforts in characterizing child neurology. In a prolific and highly influential carrier, Bill
Genetic Testing Clinical geneticists have an acute need to understand pathogenicity in genomes of their patients (Figure 1). Cost per human genome has now approached
How to better understanding Variants of Uncertain Significance in epilepsy and help find new therapeutic approaches Did you know that 1 in 26 people will